Synergy Pharmaceuticals’ Chief Scientific Officer to Present Plenary Lecture
at the 2014 Southern Regional Meetings
NEW YORK -- February 19, 2014
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced its Chief
Scientific Officer, Kunwar Shailubhai, Ph.D., M.B.A., will present a plenary
lecture entitled, “Cyclic GMP: Understanding its Evolution and Clinical
Implications in Gastroenterology,” during the Southern Gut Club meeting being
held at the InterContinental New Orleans on Thursday, February 20, at 7:00pm
Cyclic GMP is a key intracellular mediator activated by the intestinal
guanylate cyclase-C (GC-C) receptor and is responsible for initiating
downstream GC-C signaling essential for maintenance of electrolytes and fluid
transport as well as in regulation of homeostasis in epithelial cells lining
the GI mucosa. The lecture will discuss the potential therapeutic applications
of GC-C agonists in a variety of GI diseases and disorders.
Synergy Pharmaceuticals Inc. is a biotechnology company focused on the
research and development of novel drugs for the treatment of gastrointestinal
(GI) diseases and disorders. Synergy has discovered proprietary analogs of the
human GI hormone, uroguanylin, the natural agonist for the intestinal
guanylate cyclase-C (GC-C) receptor. Both Synergy’s lead GC-C agonist,
plecanatide, and next-generation GC-C agonist, SP-333, mimic uroguanylin’s
natural functions by binding to and activating the GC-C receptor in the GI
tract to stimulate fluid and transit required for normal digestion.
Plecanatide is in phase 3 clinical trials for chronic idiopathic constipation
and a phase 2b study for irritable bowel syndrome with constipation. SP-333 is
in phase 2 development for opioid-induced constipation and is also being
explored for ulcerative colitis. For more information please visit
Synergy Pharmaceuticals Inc.
Press spacebar to pause and continue. Press esc to stop.